Skip Ribbon Commands
Skip to main content
CIBMTR

BMT CTN

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   /   Studies   /   Clinical Trials   /   BMT CTN   /   BMT CTN Protocols
  • Print
  • Share

 BMT CTN Protocols

The Blood and Marrow Transplant Clinical Trials Network (BTM CTN) offers a range of multi-institutional Phase II and III clinical trial protocols focused directly on improving survival for patients undergoing hematopoietic cell transplantation (HCT). Learn more about these protocols through the links below
 

Open to Accrual

Name ​Title
​07LT Continued Long-Tem Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702​
1101 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
​1102 ​A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Tranplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
​1201A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
1301​ ​A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease
​1302 ​Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Mulitple Myeloma
1401​​A Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions
​1502​Optimizing Cord Blood and Haploidentical Aplastic Anemia Trnasplantation (CHAMP)
1503​​A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease
​1506​A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
​1507​Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
​1601​A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
 

Closed to Accrual

Name ​Title
0101 Fluconazole versus Voriconazole after Allogeneic Transplantation
0102 Autologous/Autologous versus Autologous/Allogeneic Transplantation for Multiple Myeloma
0201 Peripheral Blood versus Bone Marrow Grafts from Unrelated Donors
0202 Autologous versus Nonmyeloablative Allogeneic Transplantation for Follicular Lymphoma
​0301 ​Conditioning Regimens in Unrelated Donor Transplantation for Aplastic Anemia
0302 Randomized Trial of Acute GVHD Therapies
0303 T-Cell Depleted Peripheral Blood Stem Cell Transplantation for AML
0401 Rituxan/BEAM versus Bexxar/BEAM with Autologous Transplantation in Diffuse Large Cell Lymphoma
0402 0402Tacrolimus/Sirolimus versus Tacrolimus/Methotrexate as GVHD Prophylaxis
0403 Etanercept for Idiopathic Pneumonia Syndrome
0501 Single versus Double Cord Blood Transplantation in Children
0502 Reduced-Intensity Conditioning in Transplantation for AML in the Elderly
​0601 Transplantation Using Reduced-Intensity Conditioning and Unrelated Donor Graft for Children with Severe Sickle Cell Disease​
0603 Haploidentical Transplantation with Reduced-Intensity Conditioning
0604 Double Cord Blood Transplantation with Reduced-Intensity Conditioning
0701 Transplantation using Reduced-Intensity Conditioning for Relapsed Follicular Lymphoma
​0702 ​Autologous Transplantation with/without Consolidation versus Tandem Autologous Transplantation with Lenalidomide Maintenance
0703 Tandem Autologous Transplantation for Recurrent Hodgkin Disease
0704 Maintenance Therapy with CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
​0801 ​Randomized Trial using Sirolimus with Other Agents for Chronic GVHD
0802 Corticosteroids with Mycophenolate Mofetil versus Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD
​0803 ​High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients
​0804 Phase II Study of Reduced-intensity Allogeneic Stem Cell Transplantation for High Risk Chronic Lymphocytic Leukemia​
​0805 Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia​
​0901 ​Myeloablative versus Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia
0902 Peri-transplant Stress Management
0903 Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodyplastic Syndromes in HIV-infected Patients
​1202​​Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
​1203 ​PROGRESS I: A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
​1204 ​Reduced-intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies
​1205​Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials.
​1304​DETERMINATION; DFCI 10-106: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
​1501​A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease
​1505​A Randomized Intervention Trial

Last Updated: 5/11/2018 11:52 AM
CIBMTR